Evotec (ETR:EVT) PT Set at €43.00 by Warburg Research

Evotec (ETR:EVTGet Rating) has been assigned a €43.00 ($46.74) price target by Warburg Research in a note issued to investors on Tuesday, Borsen Zeitung reports. Warburg Research’s target price suggests a potential upside of 59.91% from the company’s current price.

A number of other brokerages also recently weighed in on EVT. Deutsche Bank Rese… set a €33.00 ($35.87) target price on Evotec in a report on Friday, March 25th. Jefferies Financial Group set a €55.00 ($59.78) target price on Evotec in a report on Wednesday, March 2nd. Berenberg Bank set a €47.00 ($51.09) target price on Evotec in a report on Monday, February 7th. Royal Bank of Canada set a €43.00 ($46.74) target price on Evotec in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft set a €39.00 ($42.39) target price on Evotec in a report on Monday, February 7th.

Evotec stock opened at €26.89 ($29.23) on Tuesday. The stock’s 50 day moving average is €27.67 and its 200 day moving average is €35.94. The company has a debt-to-equity ratio of 50.43, a current ratio of 2.48 and a quick ratio of 2.22. The firm has a market cap of $4.76 billion and a P/E ratio of 17.97. Evotec has a one year low of €23.26 ($25.28) and a one year high of €45.83 ($49.82).

About Evotec (Get Rating)

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health.

Further Reading

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.